Wellnex Locks in Global Healthcare Giant Haleon for Another Year Until 2027
Wellnex Life secures another year with global healthcare giant Haleon
Wellnex Life Limited has extended its manufacturing partnership with Haleon, one of the world’s largest consumer healthcare companies. The Wellnex Life Haleon Agreement Extension pushes the contract expiry date to 16 March 2027, providing revenue visibility for another 12 months.
Haleon owns some of the world’s most recognised healthcare brands, including Panadol, Sensodyne, and Voltaren. The partnership, which originally commenced on 16 March 2022, now spans a total of five years, demonstrating a sustained manufacturing relationship between the Australian specialist manufacturer and the global healthcare giant.
What Wellnex supplies under this agreement
The agreement involves three parties working together to deliver soft gel liquid paracetamol products to market:
- BSPS Aust Pty Ltd (Wellnex Life’s wholly owned subsidiary) manufactures the soft gel liquid paracetamol products
- Haleon UK Trading Services Ltd receives the manufactured products under the licensing and supply agreement
- Olive Pharmascience Ltd participates as the third party to the arrangement
Wellnex manufactures these products at its Australian facilities, meeting the quality standards required by a multinational healthcare company operating across dozens of markets globally.
When big ASX news breaks, our subscribers know first
Understanding contract manufacturing in consumer healthcare
Contract manufacturing arrangements allow global healthcare companies to access specialist production capabilities without building their own manufacturing infrastructure for every product type. Companies like Haleon often partner with manufacturers who possess specific technical expertise and equipment.
Soft gel liquid formulations require specialised encapsulation technology and production lines. Rather than duplicating this capability in-house, multinational healthcare companies source from manufacturers who focus exclusively on this production method.
For smaller ASX-listed companies like Wellnex Life (ASX: WNX), securing long-term manufacturing agreements with blue-chip clients provides recurring revenue streams and validates their operational capabilities. Contract extensions signal that the supplier continues to meet stringent quality, reliability, and compliance requirements.
Management commentary
Eric Jiang, Interim Executive Chairman
“The Company is proud to continue its global partnership with Haleon, supporting their global brands with our innovative analgesic liquid soft gels.”
The next major ASX story will hit our subscribers first
What this means for Wellnex Life shareholders
The extension delivers several benefits for investors:
-
Revenue certainty extended to March 2027, providing baseline income visibility while the company pursues additional growth initiatives across its contract manufacturing business.
-
Client retention demonstrates competitive positioning in the soft gel manufacturing segment, with a five-year relationship indicating consistent delivery against multinational standards.
-
Validation from a blue-chip partner strengthens Wellnex’s credentials when pursuing new contract manufacturing opportunities with other global healthcare companies.
The announcement represents steady execution rather than business transformation. Wellnex has successfully maintained a manufacturing partnership with a globally recognised healthcare company, extending an existing agreement rather than securing new product lines or expanded volumes. The extension provides operational continuity through to early 2027.
Want the Next Healthcare Winner in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements drop across the healthcare sector.